Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man

• Principais autores: Bo Hjorth Bentzen (Autor), Sofia Hammami Bomholtz (Autor), Rafel Simó-Vicens (Autor), Lasse Folkersen (Autor), Lea Abildgaard (Autor), Tobias Speerschneider (Autor), Kalai Mangai Muthukumarasamy (Autor), Nils Edvardsson (Autor), Ulrik S. Sørensen (Autor), Morten Grunnet (Autor), Jonas Goldin Diness (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2020-05-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

AimsSmall conductance Ca2+-activated K+ channels (SK channels, KCa2) are a new target for treatment of atrial fibrillation (AF). AP30663 is a small molecule inhibitor of KCa2 channels that is currently in clinical development for treatment of AF. The aim of this study is to present the electrophysio...